Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.

Pullan PT.

Intern Med J. 2009 Apr;39(4):213-5. doi: 10.1111/j.1445-5994.2009.01916.x. No abstract available.

PMID:
19402858
2.

[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].

Steffensen C, Mægbæk ML, Laurberg P, Andersen M, Kistorp C, Nørrelund H, Dal J, Jørgensen JO.

Ugeskr Laeger. 2014 Jan 6;176(1):58-60. Review. Danish.

PMID:
24629610
3.

[Cabergoline in hyperprolactinemia and valvular heart disease].

Vargas ML, Cervantes CE, Hernando CA, Da Costa CV.

Endocrinol Nutr. 2009 Oct;56(8):412-7. doi: 10.1016/S1575-0922(09)72711-1. Review. Spanish.

PMID:
19959151
4.

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

Antonini A, Poewe W.

Lancet Neurol. 2007 Sep;6(9):826-9. Review.

PMID:
17706566
5.

[Cardiac valvulopathy and dopamine agonist].

Grandas F.

Neurologia. 2007 Dec;22(10):870-81. Review. Spanish.

PMID:
17671852
6.

[Use of dopamine agonists in the treatment of Parkinson's disease].

Gekht AB.

Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(9):54-8. Review. Russian. No abstract available.

PMID:
12378886
7.

Pergolide in the treatment of patients with early and advanced Parkinson's disease.

Bonuccelli U, Colzi A, Del Dotto P.

Clin Neuropharmacol. 2002 Jan-Feb;25(1):1-10. Review.

PMID:
11852289
8.

A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.

Kvernmo T, Härtter S, Burger E.

Clin Ther. 2006 Aug;28(8):1065-1078. doi: 10.1016/j.clinthera.2006.08.004. Review.

PMID:
16982285
9.

Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.

Valassi E, Klibanski A, Biller BM.

J Clin Endocrinol Metab. 2010 Mar;95(3):1025-33. doi: 10.1210/jc.2009-2095. Epub 2010 Feb 3. Review.

PMID:
20130078
10.

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.

Webster J.

Drug Saf. 1996 Apr;14(4):228-38. Review. Erratum in: Drug Saf 1996 May;14(5):342.

PMID:
8713691
11.

Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.

Luthra PM, Kumar JB.

Mini Rev Med Chem. 2012 Dec;12(14):1556-64. Review.

PMID:
22697513
13.
14.

Cabergoline use for pituitary tumors and valvular disorders.

Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A.

Endocrinol Metab Clin North Am. 2015 Mar;44(1):89-97. doi: 10.1016/j.ecl.2014.10.007. Epub 2014 Nov 4. Review.

PMID:
25732645
15.

Use of the dopamine agonist cabergoline in the treatment of movement disorders.

Marco AD, Appiah-Kubi LS, Chaudhuri KR.

Expert Opin Pharmacother. 2002 Oct;3(10):1481-7. Review.

PMID:
12387694
16.

Comparing dopamine agonists in Parkinson's disease.

Bonuccelli U.

Curr Opin Neurol. 2003 Dec;16 Suppl 1:S13-9. Review.

PMID:
15180133
17.

Newer therapies for Parkinson's disease.

Korczyn AD, Nisipeanu P.

Neurol Neurochir Pol. 1996;30 Suppl 2:105-11. Review. No abstract available.

PMID:
9100248
18.

Second generation of dopamine agonists: pros and cons.

Rabey JM.

J Neural Transm Suppl. 1995;45:213-24. Review.

PMID:
8748628
19.

Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KD.

Cochrane Database Syst Rev. 2001;(1):CD001519. Review.

PMID:
11279721
20.

[Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists].

Gabalec F, Čáp J, Radocha J.

Vnitr Lek. Fall 2017;63(9):561-565. Review. Czech.

PMID:
29120651

Supplemental Content

Support Center